Andrographolide inhibits the upregulation of SLC19A3 to block the adipogenic differentiation of adipose-derived stem cells.
Yang Y., Wang X., Zhou G., Hou X., He Y., Feng Y.
Laboratory Study, published in iScience (2025) — summary generated from the PubMed abstract.
Evidence from laboratory and animal studies provides groundwork for understanding mechanisms and potential before human studies continue.
- Level A · Stronger Clinical Evidence
- Level B · Emerging clinical evidence with positive signals
- Level C · Early human research exploring benefits
- Level D · Scientific groundwork from lab and animal studies
- Emerging · Emerging topic under active research
This page is generated from the PubMed record. The Thai description is an automated summary of bibliographic fields and the abstract, not a full translation, and is not medical advice.
- Study type
- Laboratory Study
- Journal
- iScience (2025)
- Country
- United States
- Reported sample size
- —
- Source database
- PubMed
- PMID
- 41531735
- PMCID
- PMC12794426
- DOI
- 10.1016/j.isci.2025.114379
Abstract (original English)
We found that andrographolide (AP), the main active component of medicinal herb Andrographis paniculata , inhibited the differentiation of adipose-derived stem cells (ADSCs) toward adipocytes in culture and in mice fed with high fat diet. RNA-seq analyses revealed that the induction of SLC19A3, a thiamine transporter, was blocked by AP, and knockdown of SLC19A3 abolished the adipogenic differentiation. Further, supplementing thiamine to cultured ADSCs reversed the inhibitory effect of AP dose-dependently, indicating that SLC19A3 mediates the action of AP on adipogenic differentiation. Interestingly, the differentiation of ADSCs was accompanied by the reduction of S9-phosphorylated GSK3β, which was prevented by AP. Subsequent investigation showed that AP and a GSK3β inhibitor upregulated Snail1, a transcriptional repressor influencing cell differentiation. While enforced expression of Snail1 reduced the luciferase activity of the SLC19A3 reporter, siRNA against Snail1 blocked the inhibition of AP on SLC19A3 expression. Thus, the GSK3β-Snail1-SLC19A3 axis mediates the anti-adipogenic action of andrographolide.
What this study does not prove
- • This study does not prove SVF is an approved treatment or a replacement for standard care.
- • This is preclinical work; animal or laboratory results cannot be applied to humans.
Evidence level
Evidence from laboratory and animal studies provides groundwork for understanding mechanisms and potential before human studies continue.
How we grade evidenceBrowse all related research
Filter the research library by this study's title keywords, author, or publication year.